Health Professional Radio - Podcast

Bob Hutchens, CEO of StemBioSys, Inc., developers of advanced stem cell technologies discusses research, which was recently published in peer-reviewed journal "Nature Scientific Reports" (Nov 2020), that demonstrates that CELLvo™ Matrix Plus, a jointly developed platform with Cartox, Inc., enables the widescale testing of experimental drugs via human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and enables maturation in seven days compared to the current partial hiPSC-CM maturation within 30 to 100 days. Matrix Plus offers the potential to significantly reduce (and one day eliminate) the need to sacrifice animals for preclinical safety studies.